Found 19 clinical trials
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
- 0 views
- 05 Aug, 2020
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI. Vitamin C is significant to human body and plays a role …
- 0 views
- 16 Feb, 2024
- 1 location
Nigella Sativa in COVID-19
Natural products with immunomodulation and antiviral activity showed a promising improvement in the outcomes of some viral infectious diseases both in preclinical and primitive clinical studies.
- 0 views
- 01 Feb, 2023
- 1 location
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that convalescent plasma does not only neutralize the pathogens but provide passive immunomodulatory properties that allows the …
- 0 views
- 16 Feb, 2024
- 1 location
Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients
To measure the effect of Ivermectin (sub-cutaneous) with or without zinc and Nigella sativa in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
- 0 views
- 16 Feb, 2024
- 1 location
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of clinical status at day 30 after study initiation.
- 0 views
- 01 Feb, 2023
- 1 location
The Renal Deterioration Between Adjusted Dose TDF and Switching to TAF in CHB With Renal Impairment
Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir. TAF has a higher plasma stability than TDF, which makes TDF require a higher dose to get the concentration of drugs in the liver equal to the …
- 0 views
- 16 Feb, 2024
- 1 location
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in …
- 0 views
- 16 Feb, 2024
- 1 location
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19
The purpose of the study is to design and execute a prospective, longitudinal, descriptive cohort study in a pragmatic clinical practice for adults with symptoms that may be related to COVID-19.
- 0 views
- 05 Aug, 2020
- 1
- 2